Position in GHRS
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$33,600
+$16,025 QoQ
Shares Held
1,250
0.0% QoQ
Ownership
0.002%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#53
of 62 holders
Holding Since
Mar 2024
10 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in GHRS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026WELLS FARGO & COMPANY/MN holds $1,567,774,320 across 417 Biotechnology names. GHRS ranks #302 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
749,528 | $372,313,040 | |
| 2 | HALO |
Halozyme Therapeutics, Inc.
|
1,390,428 | $108,828,797 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
310,047 | $93,333,446 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
140,802 | $87,795,677 | |
| 5 | EXEL |
Exelixis, Inc.
|
717,840 | $39,057,673 | |
| 6 | RVMD |
Revolution Medicines, Inc.
|
178,780 | $33,481,916 | |
| 7 | ARGX |
Argenx SE
|
34,453 | $31,964,458 | |
| 8 | INCY |
Incyte Corp
|
255,064 | $28,914,053 |
All Filings in GHRS
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $33,600 | 1,250 | Shares | Defined | 2026-08-14 | |
| 2026-03-31 | $17,575 | 1,250 | Shares | Defined | 2026-05-11 | |
| 2025-12-31 | $15,875 | 1,250 | Shares | Defined | 2026-02-13 | |
| 2025-09-30 | $17,875 | 1,250 | Shares | Defined | 2025-11-13 | |
| 2025-06-30 | $15,237 | 1,250 | Shares | Defined | 2025-08-14 | |
| 2025-03-31 | $13,787 | 1,250 | Shares | Defined | 2025-05-13 | |
| 2024-12-31 | $8,750 | 1,250 | Shares | Defined | 2025-02-13 | |
| 2024-09-30 | $8,362 | 1,250 | Shares | Defined | 2024-11-13 | |
| 2024-06-30 | $14,575 | 1,250 | Shares | Defined | 2024-08-13 | |
| 2024-03-31 | $13,325 | 1,250 | Shares | Defined | 2024-05-10 | |
| No filing history on record for this holder in this stock. | ||||||